Evolus posts scientific investor presentation on Jeuveau, Evolysse HA fillers, Profhilo skin-quality injectable portfolio
EOLS•Evolysse pivotal study results
Evolysse Form and Smooth showed non-inferiority at 6 months versus Restylane-L in a U.S. pivotal nasolabial fold study of 140 patients.
The primary endpoint analysis also showed statistical superiority at 6 months, with 95% CI [-0.5, -0.032] for Form and [-0.416, -0.019] for Smooth.
Safety in the pivotal study was described as similar to control, with 0 serious adverse events and 0 delayed-onset nodules for both products.
Evolus highlights broader aesthetics portfolio
Evolus highlighted a broader aesthetics portfolio built around Jeuveau neurotoxin, Evolysse hyaluronic acid fillers, and Profhilo skin-quality injections.
Profhilo positioned as a leading skin-quality injectable
Profhilo was positioned as a European market-leading skin-quality injectable, cited as 4.8 million treatments across 70+ countries.
